<DOC>
	<DOCNO>NCT00703677</DOCNO>
	<brief_summary>The goal trial evaluate safety tolerability lithium people progressive supranuclear palsy corticobasal degeneration .</brief_summary>
	<brief_title>A Pilot Trial Lithium Subjects With Progressive Supranuclear Palsy Corticobasal Degeneration</brief_title>
	<detailed_description>Progressive supranuclear palsy ( PSP ) corticobasal degeneration ( CBD ) progressive , adult-onset neurodegenerative disorder characterize accumulation hyperphosphorylated tau . Symptomatic treatment minimal benefit individual PSP CBD , effective disease modify agent . Tau phosphorylation regulate part enzyme GSK-3β ( glycogen synthase kinase-3 beta ) . Inhibition enzyme may benefit individual PSP CBD decreasing level phosphorylated tau . Lithium known inhibit GSK-3β , thus , may rational therapeutic approach . The primary objective study determine safety tolerability lithium people PSP CBD . Additionally , study evaluate potential biomarkers clinical outcome measure well assess study drug compliance . In multicenter , open label study , 45 eligible participant PSP CBD receive study drug , lithium . The dosage lithium titrate 5-week period , participant follow prospectively 6 month . Participants evaluate screen visit , baseline visit , week 2 5 titration phase . Clinic study visit occur alternate month week 28 . Telephone visit occur clinic study visit .</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>1 . Able give inform consent 2 . Able comply study protocol , include ability attend followup study visit duration study 3 . Diagnosis PSP CBD base follow criterion : 1 . Probable PSP : Gradually progressive akinetic disorder Unequivocal prominent slow vertical saccade vertical supranuclear gaze palsy Early prominent postural instability early fall Poor absent response levodopa 2 . Probable CBD : Chronic progressive course Asymmetric onset Presence high cortical dysfunction ( apraxia , apraxia speech , nonfluent aphasia , cortical sensory loss , alien limb ) Movement disorder : rigid/akinetic syndrome resistant levodopa either dystonic limb posture focal myoclonus limb ( spontaneous stimulus sensitive ) 4 . If psychotropic antiparkinsonian medication take ( e.g. , anxiolytic , hypnotic , benzodiazepine , antidepressant , levodopa , amantadine ) , dosage must stable 28 day prior screen visit maintain constant dosage throughout study , possible 5 . If NSAIDs , ACEIs , ARBs , thiazide diuretic , COX2 inhibitor theophylline take subject , dosage must stable 28 day prior screen visit maintain constant dosage throughout study , possible . 6 . Creatinine clearance &gt; 50 ml/min 7 . Able take oral medication 8 . Women must able become pregnant ( e.g. , post menopausal , surgically sterile use adequate birth control method duration study . ) 9 . Able identify study partner 1 . Evidence disease could explain clinical presentation 2 . History known sensitivity intolerability lithium know ingredient study drug 3 . Exposure investigational agent within 28 day screen visit 4 . Clinically significant cardiac disease EKG find 5 . Other serious illness , include psychiatric illness ( `` serious illness '' define illness unstable enough might jeopardize subject 's ability complete study ) 6 . Moderate severe ongoing depression 7 . Family history `` PSP '' `` CBS '' 8 . Clinically significant abnormality screen visit laboratory result 9 . Any AE ≥ Grade 3 list CTCAE , version 3.0 10 . Women pregnant breastfeed 11 . History brain surgery 12 . Use potential GSK3β inhibitor ( e.g. , valproic acid ) 13 . Use iodide salt [ e.g. , calcium iodide , hydrogen iodide ( hydriodic acid ) , iodide , iodinate glycerol ( Organidin ) , iodine , potassium iodide ( SSKI ) , sodium iodide ] 14 . Previous use lithium 15 . Use Coenzyme Q10 dosage great 600 mg day NanoQuinon dosage great 150mg day 2.5 mg/kg day 16 . Active psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>progressive supranuclear palsy</keyword>
	<keyword>corticobasal degeneration</keyword>
	<keyword>PSP</keyword>
	<keyword>CBD</keyword>
	<keyword>lithium</keyword>
	<keyword>tau</keyword>
</DOC>